ZURA on Nasdaq

Zura Bio Ltd

In its 2026 annual report the company says: “We are a clinical-stage biotechnology company developing novel and differentiated medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with significant unmet medical need. We focus on targets for which human data, including biomarker findings, genetic associations and prior clinical studies, inform therapeutic rationale and development decisions.”4 It is headquartered in La Jolla, California.1 Its shares trade on Nasdaq under the symbol ZURA.1

Price unavailable

Last updated Oct 20, 2026.

Overview

Compare with another stock.

  • TickerZURA on Nasdaq1
  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersLa Jolla, California1
  • Incorporated inCayman Islands2
  • Business address4225 Executive Square, Suite 600, La Jolla, Ca 920372
  • Filer category, Emerging growth company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

We are a clinical-stage biotechnology company developing novel and differentiated medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with significant unmet medical need. These diseases are often chronic, biologically complex and difficult to treat, and many patients do not achieve durable disease control with currently available therapies.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income567-$75.2M in 2025+177% since 2022
-$80.0M-$60.0M-$40.0M-$20.0M02022: -$27.2M-$27.2M20222023: -$62.6M-$62.6M2023+131%2024: -$55.2M-$55.2M2024−12%2025: -$75.2M-$75.2M2025+36%
Net income567-$68.7M in 2025+167% since 2022
-$80.0M-$60.0M-$40.0M-$20.0M02022: -$25.7M-$25.7M20222023: -$60.4M-$60.4M2023+135%2024: -$52.4M-$52.4M2024−13%2025: -$68.7M-$68.7M2025+31%

Every line of the income statement as filed: the last 2 fiscal years, latest first.7

Period ending2025-12-312024-12-31
Research and development$42.1M$24.4M
General and administrative$33.2M$30.8M
Total operating expenses$75.2M$55.2M
Loss from operations-$75.2M-$55.2M
Interest income-$6.3M-$8.0M
Change in fair value of private placement warrants$5.2M
Other income, net-$260.0K-$28.0K
Total other income, net-$6.6M-$2.8M
Loss before income taxes-$68.7M-$52.4M
Net loss-$68.7M-$52.4M
Adjustment of redeemable noncontrolling interest$831.0K$7.0M
Accretion of redeemable noncontrolling interest to redemption value$4.9M
Deemed dividend on extinguishment of noncontrolling interest and redeemable noncontrolling interest-$36.4M
Net loss attributable to Class A Ordinary Shareholders of Zura-$99.4M-$45.4M
Net loss per share attributable to Class A Ordinary Shareholders of Zura, basic (in dollars per share)-$1.06-$0.60
Net loss per share attributable to Class A Ordinary Shareholders of Zura, diluted (in dollars per share)-$1.06-$0.60
Weighted-average Class A Ordinary Shares used in computing net loss per share attributable to Class A Ordinary Shareholders of Zura, basic (in shares)94.2M shares75.1M shares
Weighted-average Class A Ordinary Shares used in computing net loss per share attributable to Class A Ordinary Shareholders of Zura, diluted (in shares)94.2M shares75.1M shares

Compare Zura Bio Ltd with another company

Corporate structure

Zura Bio Ltd sits at the top of its group. 2 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Zura Bio Ltd

  • GREAT POINT PARTNERS LLC Filed SCHEDULE 13G/A on Zura Bio Ltd, latest May 15, 2026 (8 filings since Jun 16, 2023)
  • Venrock Healthcare Capital Partners III, L.P. Filed SCHEDULE 13G/A on Zura Bio Ltd, latest May 15, 2026 (5 filings since May 2, 2024)
  • MONTANOVA CAPITAL, LLC Filed SCHEDULE 13G/A on Zura Bio Ltd, latest May 12, 2026 (4 filings since Jun 15, 2023)
  • JPMorgan Chase Filed SCHEDULE 13G/A on Zura Bio Ltd, latest May 6, 2026 (2 filings since Jul 16, 2025)
  • AI Biotechnology LLC Filed SCHEDULE 13D/A on Zura Bio Ltd, latest Mar 2, 2026 (2 filings since May 28, 2025)
  • Athanor Capital Filed SCHEDULE 13D on Zura Bio Ltd, latest Jan 27, 2026 (2 filings since Jan 2, 2026)
  • Deep Track Capital, LP Filed SCHEDULE 13G/A on Zura Bio Ltd, latest Nov 14, 2025 (5 filings since Jun 15, 2023)
  • ADAR1 Capital Management, LLC Filed SCHEDULE 13G/A on Zura Bio Ltd, latest Feb 14, 2025 (2 filings since Nov 14, 2024)
  • RA CAPITAL MANAGEMENT, L.P. Filed SCHEDULE 13G/A on Zura Bio Ltd, latest Feb 14, 2025 (2 filings since May 2, 2024)
  • Pfizer Filed SCHEDULE 13G/A on Zura Bio Ltd, latest Feb 12, 2025 (2 filings since Mar 30, 2023)
  • Athanor Capital, LP Filed SC 13G/A on Zura Bio Ltd, latest Sep 23, 2024 (4 filings since Mar 31, 2023)
  • ACCESS INDUSTRIES MANAGEMENT, LLC Filed SC 13G/A on Zura Bio Ltd, latest Feb 14, 2024 (2 filings since Jun 15, 2023)
  • Zura Bio Ltd La Jolla, California
    • Zura Bio Limited, a limited company incorporated under the laws of England and Subsidiary · United Kingdom

Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Zura Bio Ltd reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$126.0K7 Dec 31, 2025$91.0K7 Dec 31, 2024+38.5%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$109.4M7 Dec 31, 2025$176.5M7 Dec 31, 2024−38.0%

Properties, in its own words

We do not own any real property. We currently lease executive offices at 1489 W. Warm Springs Rd., #110, Henderson, Nevada and 8-10 Hill Street, London, W1J 5NG. We consider our current office space adequate for our current operations.

Item 2 of the 10-K filed Mar 19, 2026.4

Leadership

Who has led Zura Bio Ltd, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Someit Sidhu2023
  2. Robert Lisicki2024–2026
  3. Sandeep Chidambar Kulkarni2026–now

President

  1. Preston Klassen2023

Chief financial officer

  1. Verender S. Badial2021–2025
  2. Eric J. Hyllengren2025–now

Chief operating officer

  1. Mir Tauhid Ali2021
  2. Preston Klassen2023
2025
Board members and other officers (22)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive OfficerMichael Howell named May 5, 2023 to May 6, 202439
  • DirectorArnout Ploos van Amstel named May 6, 202439
  • DirectorNeil Graham named May 5, 2023 to May 6, 202439

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • Zura Bio Limited, a limited company incorporated under the laws of England and Wales3

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

  • JATT Acquisition CorpApr 8, 2021 to Mar 21, 20232

Timeline

  1. Aug 17, 20268-K Regulation FD disclosure40
  2. Aug 11, 20268-K Results of operations; Regulation FD disclosure41
  3. Jul 1, 20268-K Regulation FD disclosure42
  4. Jun 18, 20268-K Executive or director change; Shareholder vote43
  5. May 22, 20268-K Executive or director change44
  6. May 7, 20268-K Results of operations; Regulation FD disclosure45
  7. Apr 23, 20268-K Executive or director change46
  8. Mar 19, 20268-K Results of operations; Regulation FD disclosure47
  9. Mar 10, 20268-K Regulation FD disclosure48
  10. Mar 5, 20268-K Regulation FD disclosure49
  11. Feb 26, 20268-K Entered a material agreement; Results of operations; Other events50
  12. Feb 26, 20268-K Financial statements and exhibits51
  13. Jan 23, 2026New chief executive Sandeep Chidambar Kulkarni becomes CEO11
  14. Jun 21, 2024New chief executive Robert Lisicki becomes CEO12
  15. Feb 15, 2023New chief executive Someit Sidhu becomes CEO13

Calendar

Coming up

  1. Nov 12, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.21) a share, on Nov 13, 2025.52

When it reported results

  1. Aug 11, 2026Reported quarterly or annual results41
  2. May 7, 2026Reported quarterly or annual results45
  3. Mar 19, 2026Reported quarterly or annual results47
  4. Feb 26, 2026Reported quarterly or annual results50
  5. Nov 13, 2025Reported quarterly or annual results53
  6. Aug 14, 2025Reported quarterly or annual results54
  7. May 8, 2025Reported quarterly or annual results55
  8. Mar 25, 2025Reported quarterly or annual results56

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

412 filings to the SEC since October 2021: 5 annual reports, 17 quarterly reports, 98 major events, 117 insider forms, 52 large holders, 2 private raises, 121 other. The latest 20:

  1. Sep 30, 2026S-8 EDGAR
  2. Aug 18, 2026144 EDGAR
  3. Aug 17, 2026144 EDGAR
  4. Aug 17, 20268-K EDGAR
  5. Aug 14, 2026144 EDGAR
  6. Aug 13, 2026144 EDGAR
  7. Aug 11, 20268-K EDGAR
  8. Aug 11, 202610-Q EDGAR
  9. Jul 1, 20268-K EDGAR
  10. Jun 22, 20263 EDGAR
  11. Jun 22, 20264 EDGAR
  12. Jun 22, 20264 EDGAR
  13. Jun 22, 20264 EDGAR
  14. Jun 22, 20264 EDGAR
  15. Jun 22, 20264 EDGAR
  16. Jun 22, 20264 EDGAR
  17. Jun 22, 20264 EDGAR
  18. Jun 18, 20268-K EDGAR
  19. May 22, 2026DEFA14A EDGAR
  20. May 22, 20268-K EDGAR

The 412 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

11 open-market trades by officers, directors and large owners since October 2021: 7 buys and 4 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Feb 26, 2026Access Industries Holdings LLC10% ownerBuy2,000,000$6.25$12.5MForm 4
Nov 25, 2024Thiara ParvinderDirectorSale1,001,633$2.73$2.7MForm 4
Sep 11, 2024Thiara ParvinderDirectorSale3,800,000$2.70$10.3MForm 4
Sep 4, 2024Sidhu SomeitDirectorSale51,728$3.87$200.2KForm 4
May 17, 2024Ploos van Amstel ArnoutDirectorBuy80,000$6.20$496.0KForm 4
Apr 22, 2024Howell MichaelSee RemarksBuy7,987$3.13$25.0KForm 4
Apr 22, 2024Nistala KiranSee RemarksBuy3,195$3.13$10.0KForm 4
Apr 22, 2024Munshi AmitDirectorBuy159,744$3.13$500.0KForm 4
Apr 22, 2024Sidhu SomeitDirectorBuy1,186,901$3.13$3.7MForm 4
Dec 12, 2023Thiara ParvinderDirectorSale2,000,000$4.00$8.0MForm 4
Jun 5, 2023Munshi AmitDirectorBuy117,647$4.25$500.0KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Robert Lisicki Former Chief Executive Officer$624.0K$1.7M76
2025Kim Davis Chief Operating Officer, Chief Legal Officer and Corporate Secretary; Former Interim Chief Executive Officer58$486.4K$1.3M76
2025Eric Hyllengren Former Chief Financial Officer$230.3K$1.0M76
2025Kiran Nistala Chief Medical Officer and Head of Development54$468.3K$1.0M76
2024Robert Lisicki Former Chief Executive Officer$537.8K$6.7M76
2024Kiran Nistala Chief Medical Officer and Head of Development54$409.6K$2.5M76
2024Kim Davis Chief Operating Officer, Chief Legal Officer and Corporate Secretary; Former Interim Chief Executive Officer58$437.4K$1.8M76

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Apr 22, 2024Raised $112.5 million in a private offering of equity Form D: $112.5 million offered in all Form D
  2. May 1, 2023Raised $15.9 million in a private offering of equity Form D: $80 million offered in all Form D

SEC filer profile

How Zura Bio Ltd is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARZura Bio Ltd1
  • CIK0001855644
  • Employer ID (EIN)98-17257364
  • Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company4
  • Incorporated inCayman Islands4
  • Fiscal year endsDecember 311
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address4225 Executive Square, Suite 600, La Jolla, CA 920371
  • Phone858-247-05201
  • Shares outstanding95,829,137 as of Aug 11, 20269
  • Public float$59.0M as of Jun 30, 20254
  • AuditorWithumSmith+Brown, PC, East Brunswick, New Jersey PCAOB ID 100; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceApr 8, 20211
  • Filings442 in all: 8-K (100), 4 (82), 3 (39), CORRESP (23), 10-Q (17), UPLOAD (17), SC 13G (15), SCHEDULE 13G/A (15)1
    All 50 form types

    SC 13G/A (14), 425 (13), EFFECT (9), S-4/A (9), 10-K (5), 144 (5), 424B3 (5), DEF 14A (5), S-1/A (5), 4/A (4), ARS (3), POS AM (3), S-1 (3), SC 13D (3), SCHEDULE 13G (3), 10-Q/A (2), 424B5 (2), 424B7 (2), 5 (2), 8-A12B (2), 8-K/A (2), CERT (2), D (2), DEFA14A (2), DRS (2), PRE 14A (2), S-3/A (2), S-4 (2), S-8 (2), SC 13D/A (2), SC TO-I/A (2), SCHEDULE 13D (2), SEC STAFF LETTER (2), 25 (1), 25-NSE (1), 424B4 (1), DEFR14A (1), NT 10-K (1), NT 10-Q (1), S-3 (1), SC TO-I (1), SCHEDULE 13D/A (1)

  • Latest filingsAnnual report (10-K) Mar 19, 2026
    Quarterly report (10-Q) Aug 11, 2026
    Proxy statement (DEF 14A) Apr 30, 2026
    Latest 8-K (8-K) Aug 17, 2026

Securities registered for trading

ClassSymbolExchange
Class A Ordinary Shares, par value $0.0001 per shareZURANasdaq

From the cover page of the 10-K filed Mar 19, 2026 (Section 12(b) of the Exchange Act).4

Risk factors and legal proceedings

The risks Zura Bio Ltd names in Item 1A of its 10-K filed Mar 19, 2026: 74 risks under these headings, as written.4

  • Risks Related to Our Limited Operating History, Financial Position and Capital Requirements
  • We have a limited operating history, have not completed any clinical trials, and have not taken a product through to commercialization.
  • We have incurred losses since inception, and we expect to incur significant losses for the foreseeable future and may not be able to achieve or sustain profitability in the future. We have not generated any revenue from the ZB Assets and may never generate revenue or become profitable.
  • Our recurring losses from operations and financial condition could raise substantial doubt about our ability to continue as a going concern.
  • If we are unable to raise capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our development programs or future commercialization efforts.
  • Due to the significant resources required for the development of the ZB Assets, we must prioritize the pursuit of treatments for certain indications. We may expend our limited resources to pursue a particular indication and fail to capitalize on indications that may be more profitable or for which there is a greater likelihood of success.
  • We may in the future license additional assets, which may require us to expend additional resources and raise additional capital.
  • Risks Related to Anticipated Timing for Initiation, Enrollment, and Completion of Any Planned or Future Clinical Trials
  • We may not be able to initiate clinical trials if drug product is not timely available at clinical trial sites.
  • Risks Related to the Clinical Development and Commercialization of Our Product Candidates
  • We have never successfully completed the regulatory approval process for any product candidates and we may be unable to do so for any product candidates we develop.
  • We are substantially dependent on the success of the ZB Assets, and our ongoing and anticipated clinical trials of the ZB Assets may not be successful.
The other 63 risks
  • The results of preclinical studies and early clinical trials of the ZB Assets may not be predictive of the success of our later clinical trials, and the results of our clinical trials may not satisfy the requirements of the FDA, EMA, or other foreign regulatory authorities.
  • Preclinical and clinical development involves a lengthy and expensive process with uncertain outcomes, and results of earlier studies and trials may not be predictive of future clinical trial results.
  • Preliminary, interim data from our clinical trials that we announce or publish may change as more patient data become available and are subject to audit and verification procedures.
  • We may develop the ZB Assets in combination with other therapies, which exposes us to additional risks related to other agents or active pharmaceutical or biological ingredients used in combination with our product candidates.
  • If the FDA or other regulatory authorities revoke their approval of these other therapies or revoke their approval of, or if safety, efficacy, manufacturing or supply issues arise with, the therapies we choose to evaluate in combination with any product candidate we develop, we may be unable to obtain approval.
  • The ZB Assets may have a safety profile that could prevent regulatory approval, marketing approval or market acceptance, or limit commercial potential.
  • Risks Related to our Dependence on Third Parties or Their Actions
  • We intend to rely on third parties to conduct, supervise, and monitor our preclinical studies and clinical trials, and if those third parties perform in an unsatisfactory manner, it may harm our business.
  • We do not have our own manufacturing capabilities and will rely on third parties to produce clinical and commercial supplies of our product candidates. Reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or such quantities at an acceptable cost.
  • Risks Related to Our Intellectual Property
  • Our business relies on certain licensing rights from Lilly for tibulizumab that can be terminated in certain circumstances. If we breach the agreement, or if we are unable to satisfy our obligations under which we license rights to tibulizumab from Lilly, we could lose the ability to develop and commercialize tibulizumab.
  • Our business relies on certain licensing rights from Pfizer for crebankitug that can be terminated in certain circumstances. If we breach the agreement, or if we are unable to satisfy our obligations under which we license rights to torudokimab from Pfizer, we could lose the ability to develop and commercialize crebankitug.
  • Our business relies on certain licensing rights from Lilly for torudokimab that can be terminated in certain circumstances. If we breach the agreement, or if we are unable to satisfy our obligations under which we license rights to torudokimab from Lilly, we could lose the ability to develop and commercialize torudokimab.
  • Intellectual property disputes may impact our business and/or our ability to develop and commercialize the ZB Assets.
  • Our ability to protect our patents and other proprietary rights is uncertain, exposing us to the possible loss of competitive advantage.
  • We have limited geographical protection with respect to our licensed patents and may not be able to protect our intellectual property rights throughout the world.
  • Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated if we fail to comply with these requirements.
  • Issued patents covering one or more of our product candidates could be found invalid or unenforceable.
  • We may not be able to maintain or enforce trade secret protection for our product candidates.
  • We may be subject to damages resulting from claims that we or our employees have wrongfully used or disclosed confidential information of our competitors or are in breach of non-competition or non-solicitation agreements with our competitors.
  • Patent terms may not protect our competitive position with respect to the ZB Assets for an adequate amount of time.
  • If we do not obtain patent term extensions in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation, our business may be materially harmed.
  • Changes to patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect or capitalize on the ZB Assets.
  • We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market the ZB Assets.
  • We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.
  • We may be subject to patent infringement claims or may need to file claims to protect our intellectual property, which could result in substantial costs and liability and prevent us from commercializing the ZB Assets.
  • Our license from Pfizer is subject to retained rights.
  • Our licenses from Lilly are subject to retained rights.
  • We may not be able to effectively secure first-tier technologies when competing against other companies or investors.
  • Numerous factors may limit any potential competitive advantage provided by our intellectual property rights.
  • If approved, our product candidates that are regulated as biologics may face competition from biosimilars or interchangeables approved through an abbreviated regulatory pathway.
  • Risks Related to Regulatory and Legal Compliance
  • The regulatory approval processes of the FDA, EMA, and other foreign regulatory authorities are complex, time-consuming and inherently unpredictable. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for the ZB Assets, we may not be able to commercialize, or may be delayed in commercializing, the ZB Assets, and our ability to generate revenue will be materially impaired.
  • Of the large number of products in development, only a small percentage successfully complete the FDA, EMA, or foreign regulatory approval processes and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market the ZB Assets, which would significantly harm our business, results of operations and prospects.
  • We will be subject to extensive ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with the ZB Assets.
  • Due to unfavorable pricing regulations and/or third-party coverage and reimbursement policies, we may not be able to offer the ZB Assets at competitive prices which would seriously harm our business.
  • The FDA, EMA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses.
  • Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.
  • Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.
  • The size of the potential market for the ZB Assets is difficult to estimate and, if any of our assumptions are inaccurate, the actual markets for our product candidates may be smaller than our estimates.
  • Healthcare legislative and regulatory reform discourse and potential or enacted measures may have a material adverse impact on our business and results of operations and legislative or political discussions surrounding the desire for and implementation of pricing reforms may adversely impact our business.
  • If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.
  • We are subject to laws and regulations related to privacy, data protection, information security and consumer protection across different markets where we conduct our business. Our actual or perceived failure to comply with such obligations could harm our business.
  • International trade policies, including tariffs, sanctions and trade barriers may adversely affect our business, financial condition, results of operations and prospects.
  • Risks Related to Our Business Operations, Employee Matters, and Managing Growth
  • We are dependent on our key personnel and anticipate hiring additional key personnel. If we are not successful in attracting and retaining qualified personnel, including consultants, we may not be able to successfully implement our business strategy.
  • We rely on third parties, including consultants, independent clinical investigators and CROs to conduct and sponsor some of the clinical trials of our product candidates. Any failure by a third party to meet its obligations with respect to the clinical development of our product candidates may delay or impair our ability to obtain regulatory approval for our product candidates.
  • In order to successfully implement our plans and strategies, we will need to grow the size of our organization and we may experience difficulties in managing this growth.
  • Our internal computer systems, or those of any of the third parties with whom we work (including CROs, manufacturers, other contractors or consultants or potential future collaborators), may fail or suffer security or data privacy breaches or other unauthorized or improper access to, use of, or destruction of our proprietary or confidential data, employee data or personal data, which could result in additional costs, loss of revenue, significant liabilities, harm to our brand and material disruption of our operations.
  • We currently rely, and plan to rely in the future, on third parties to conduct and support our preclinical studies and clinical trials. If these third parties do not properly and successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize the ZB Assets.
  • We intend to rely on third parties to manufacture the ZB Assets. There can be no assurance that we will successfully negotiate future agreements with third-party manufacturers for the ZB Assets on acceptable terms or at all. Our business could be adversely affected if the third-party manufacturers are unable to produce the ZB Assets, fail to provide us with sufficient quantities of the ZB Assets or fail to do so at acceptable quality levels or prices.
  • We may, in the future, form or seek collaborations or strategic alliances or enter into licensing arrangements, and we may not realize the benefits of such collaborations, alliances or licensing arrangements.
  • Our financial condition, results of operations and business reputation could be adversely affected by our recent internal review of certain agreements and other matters.
  • The increasing use of social media platforms presents new risks and challenges.
  • Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
  • We may identify material weaknesses in our internal control over financial reporting in the future or fail to maintain an effective system of internal control over financial reporting, which may result in material misstatements of our consolidated financial statements or cause us to fail to meet periodic reporting obligations.
  • If we fail to maintain an effective system of disclosure controls and internal control over financial reporting, our ability to produce timely and accurate financial statements or comply with applicable regulations could be impaired, which may adversely affect investor confidence in Zura and, as a result, the market price of our ordinary shares.
  • Increasing regulatory focus on privacy and security issues and expanding laws and regulatory requirements could impact our business models and expose us to increased liability.
  • We face substantial competition, which may result in others discovering, developing, licensing or commercializing products before or more successfully than we do.
  • Public health crises such as pandemics or similar outbreaks have affected and could continue to seriously and adversely affect our preclinical studies and anticipated clinical trials, business, financial condition and results of operations.
  • Our business, operations, financial position, and clinical development plans and timelines could be materially adversely affected by international conflicts and economic sanctions.
  • Risks Related to Ownership of Our Class A Ordinary Shares
  • The market price of our securities may be volatile and may decline in the future.
  • We have not paid cash dividends in the past and we do not expect to pay cash dividends in the foreseeable future. Any return on investment may be limited to the capital appreciation, if any, of our Class A Ordinary Shares.
  • Future sales and/or issuances of our securities could result in additional dilution of the percentage ownership of our existing shareholders and could cause our share price to fall.
  • If certain holders of our Class A Ordinary Shares sell a significant portion of their securities, it may negatively impact the market price of our Class A Ordinary Shares and such holders still may receive significant proceeds.
  • Our operating results have and may continue to fluctuate significantly.
  • The absence, reduction, or unfavorable nature of securities or industry analyst coverage of our business, as well as unfavorable third‑party reports or commentary and the existence of pre‑funded warrants, could adversely affect the market price and trading volume of our Class A ordinary shares.

Legal proceedings

We are not currently a party to any material legal proceedings, nor are we aware of any material pending or threatened litigation. In the ordinary course of business, we may be subject to legal proceedings, claims, and litigation.

The opening of Item 3, Legal Proceedings.4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76